Literature DB >> 7616396

Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides.

A Bourson1, E Borroni, R H Austin, F J Monsma, A J Sleight.   

Abstract

The purpose of the present study was to determine possible physiological functions of the 5-ht6 receptor using antisense oligonucleotides (AOs) in male rats. Repeated intracerebroventricular treatment with AOs but not with a scrambled form of the antisense sequence (SO) gave rise to a specific behavioral syndrome of yawning, stretching and chewing and caused a 30% reduction in the number of [3H]-lysergic acid diethylamide binding sites (measured in the presence of 300 nM spiperone). Neither sequence, however, had any effect on other parameters measured (e.g., locomotor activity, body weight, food intake, body temperature and nociception). The specific behavioral syndrome did not appear to be caused by modulation of dopaminergic neurotransmission since no changes in the tissue levels of either dopamine or its metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid were seen. Furthermore, haloperidol (0.03 mg/kg s.c.) did not reduce the number of yawns or stretches. An increase in cholinergic neurotransmission did appear to be involved since the behavioral syndrome was dose-dependently antagonized by atropine. The present study suggests that 5-ht6 receptors are functionally expressed in the rat brain, where one of their functions appears to be the control of cholinergic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616396

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist.

Authors:  C Routledge; S M Bromidge; S F Moss; G W Price; W Hirst; H Newman; G Riley; T Gager; T Stean; N Upton; S E Clarke; A M Brown; D N Middlemiss
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Biodistribution and radiation dosimetry of the serotonin 5-HT₆ ligand [¹¹C]GSK215083 determined from human whole-body PET.

Authors:  Robert A Comley; Cristian Salinas; Romina Mizrahi; Irina Vitcu; Alvina Ng; William Hallett; Nicholas Keat; Alan A Wilson; Eugenii A Rabiner; Marc Laruelle; Sylvain Houle
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

3.  Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.

Authors:  Marieke Liem-Moolenaar; Mandana Rad; Stefano Zamuner; Adam F Cohen; Francesca Lemme; Kari L Franson; Joop M A van Gerven; Emilio Merlo Pich
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

4.  5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats.

Authors:  Paula D Hatcher; Verity J Brown; David S Tait; Simon Bate; Philip Overend; Jim J Hagan; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

5.  In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate.

Authors:  L A Dawson; H Q Nguyen; P Li
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Behavioural and physiological effects induced by an infusion of antisense to alpha(2D)-adrenoceptors in the rat.

Authors:  E S Robinson; D J Nutt; H C Jackson; A L Hudson
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

7.  Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.

Authors:  W D Hirst; J A Minton; S M Bromidge; S F Moss; A J Latter; G Riley; C Routledge; D N Middlemiss; G W Price
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

8.  Increased expression of the 5-HT6 receptor by viral mediated gene transfer into posterior but not anterior dorsomedial striatum interferes with acquisition of a discrete action-outcome task.

Authors:  Daniel Eskenazi; John F Neumaier
Journal:  J Psychopharmacol       Date:  2010-11-18       Impact factor: 4.153

Review 9.  5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.

Authors:  Neil Upton; Tsu Tshen Chuang; Ann J Hunter; David J Virley
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

10.  Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790.

Authors:  Marie L Woolley; Charles A Marsden; Andrew J Sleight; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.